Categories Earnings, Health Care
Earnings Summary: A snapshot of Bio-Techne’s (TECH) Q4 2024 results
Biotechnology company Bio-Techne Corporation (NASDAQ: TECH) on Wednesday announced financial results for the fourth quarter of 2024, reporting a decline in profit.
- Fourth-quarter organic revenue edged up 1% to $306.1 million; net sales moved up 2% during the three months
- Earnings per share, including special items, dropped to $0.25 in Q4 from $0.47 last year; adjusted earnings declined to $0.49 per share from $0.55 in Q4 2023
- Operating income for the fourth quarter decreased 52% to $45.8 million from $94.5 million a year earlier
- Q4 operating margin declined to 15.0% from 31.4% in the prior-year quarter, hurt mainly by impairment of assets held-for-sale, restructuring, and CEO transition costs
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
